Skip to main content

Psoriatic arthritis

      RT @AkhilSoodMD: Abstr #1037 evaluated BASDAI vs ASDAS in PsA w/ axial dx
      Both ASDAS & BASDAI showed
      - strong corr
      Abstr #1037 evaluated BASDAI vs ASDAS in PsA w/ axial dx Both ASDAS & BASDAI showed - strong correlation w/ pt pain & Global Assessment - weak correlation in tender and swollen joint counts and enthesitis #ACR22 @RheumNow #axSpA #PsA https://t.co/EunXIwzn3M
      RT @AurelieRheumo: Can we predict PsA incidence and prevalence trends?

      Germany long-term projection 2040
      3 scenarios:
      Can we predict PsA incidence and prevalence trends? Germany long-term projection 2040 3 scenarios: 1. increase 5%/yr 2. stable 3. decrease 5%/yr. Best scenario (3) = peak diagnoses in 2028. Are medical resources ready for it? https://t.co/ws87zDukuM Abs#1019 #ACR22 @Rheumnow https://t.co/dqkfrag0w2
      RT @DrPetryna: #abst1012 #acr22 @rheumnow CASIPSA Study of SI CT in 48 PsA pts vs 48 controls. Disease duration 22.87
      2 years ago
      #abst1012 #acr22 @rheumnow CASIPSA Study of SI CT in 48 PsA pts vs 48 controls. Disease duration 22.87 ± 14.95 y, 43.48 %HLA-B27+. higher prevalences of erosion in PsA (18%) preferentially located on the anterior and middle regions of the SIJs https://t.co/4dtJNCKf4I
      RT @uptoTate: axPsA and AS adult pts exhibit different genetic risk factors & serum IL-17 levels. GUS demonstrated s
      axPsA and AS adult pts exhibit different genetic risk factors & serum IL-17 levels. GUS demonstrated significant pharmacodynamic effects and clinical improvement in axPsA and non-axPsA pts. Abs 1038 #ACR22 @RheumNow https://t.co/9Rjw7usO8J
      RT @synovialjoints: JAK and TYK-2 inhibitors and indications in SpA:

      ● Tofacitinib ➣ Pan JAKi (AS, PsA)
      ● Baricit
      JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
      RT @RHEUMarampa: Differences between #uveitis pattern in AS vs. PsA and IBD 👇

      This is always asked to our rheum fell
      2 years ago
      Differences between #uveitis pattern in AS vs. PsA and IBD 👇 This is always asked to our rheum fellows during Kelley's hour 🤓 #ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06
      Minimal Disease Activity, MDA, criteria are used to evaluate PsA disease activity and response to treatment. For reference, MDA is defined as meeting ≥5 criteria: tender joint count ≤1, swollen joint…